{
    "id": "5e29f959aa19d74431000004",
    "question": "Can LB-100 sensitize ovarian carcinoma to cisplatin?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to look for any information related to LB-100 and its effect on cisplatin sensitivity in ovarian carcinoma. However, the provided documents do not mention LB-100 at all. Therefore, we can only rely on general knowledge about the topic.\\n\\nIn ovarian carcinoma, LB-100 is not a known compound or drug. Cisplatin is a well-known platinum-based chemotherapy drug used to treat ovarian cancer, and its sensitivity can be enhanced by various factors, including certain drugs or agents. However, without specific information about LB-100, we cannot determine its effect on cisplatin sensitivity.\\n\\nTherefore, based on the available information, we can only conclude that we do not have enough data to answer this question accurately.\\n\\nHowever, considering the general knowledge about the topic, I will provide an answer based on the general principles of cancer treatment.\\n\\nIn general, sensitization of cancer cells to chemotherapy agents like cisplatin can be achieved through various mechanisms, such as increasing the expression of drug transporters, modifying DNA repair pathways, or enhancing the generation of reactive oxygen species. Some compounds, like LB-100, might have potential to sensitize cancer cells to cisplatin by modulating these pathways. However, without specific information about LB-100, we cannot determine its effectiveness in sensitizing ovarian carcinoma to cisplatin.\\n\\nGiven the lack of information about LB-100, the correct answer would be based on the assumption that LB-100 is not a known compound or drug that affects cisplatin sensitivity in ovarian carcinoma.\\n\\nTherefore, the answer would be:\\n\\nAnswer Choice: B. no\\n\\nHowever, please note that this answer is based on the assumption that LB-100 is not a known compound or drug, and its actual effect on cisplatin sensitivity in ovarian carcinoma may be different.\\n\\nIf we consider the general knowledge about the topic, we can say that LB-100 might not sensitize ovarian carcinoma to cisplatin, but this is not a definitive answer without more information about LB-100.\", \"answer_choice\": \"B\"}}",
    "snippets": [
        {
            "id": "Gynecology_Novak_7320",
            "title": "Gynecology_Novak",
            "content": "Platinum-Sensitive Disease The use of combination platinum plus paclitaxel chemotherapy versus a single-agent platinum was tested in two multinational randomized phase III trials and a randomized phase II study (292,293). In a report of the ICON4 and AGO-OVAR-2.2 (AGO Studiengruppe Ovarialkarzinom) trials, 802 women with platinum-sensitive ovarian cancer, who relapsed after being treatment free for at least 6 to 12 months were randomized to platinum-based chemotherapy (72% carboplatin or cisplatin alone; 17% CAP; 4% carboplatin plus cisplatin; and 3% cisplatin plus doxorubicin)or paclitaxel plus platinum-based chemotherapy (80% paclitaxel plus carboplatin; 10% paclitaxel plus cisplatin; 5% paclitaxel plus both carboplatin and cisplatin; and 4% paclitaxel alone) (292). The AGO-OVAR-2.2 trial did not accrue its planned number of patients. In both trials, a significant proportion of the patients did not receive paclitaxel as part of their initial chemotherapeutic regimen. Combining the"
        },
        {
            "id": "Gynecology_Novak_7505",
            "title": "Gynecology_Novak",
            "content": "259. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9:389\u2013393. 260. Gore ME, Fryatt I, Wiltshaw E, et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990;36:207\u2013211. 261. Markman M, Markman J, Webster K, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004;22:3120\u20133125. 262. Markman M. Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: what is optimal treatment? Gynecol Oncol 2001;81:1\u20132. 263. Cannistra SA. Is there a \u201cbest\u201d choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? J Clin Oncol 2002;20:1158\u20131160. 264."
        },
        {
            "id": "Gynecology_Novak_7514",
            "title": "Gynecology_Novak",
            "content": "294. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006;24:4699\u2013 4707. 295. Alberts DS, Liu PY, Wilczynski SP, et al. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol 2008;108:90\u201394. 296. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010;28:3323\u20133329. 297."
        },
        {
            "id": "Gynecology_Novak_7493",
            "title": "Gynecology_Novak",
            "content": "209. The ICON Collaborators. International Collaborative Ovarian Neoplasm Study 2 (ICON2): randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. Lancet 1998;352:1571\u20131576. 210. Vasey PA, Paul J, Birt A, et al. Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group. J Clin Oncol 1999;17:2069\u20132080. 211. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III tiral of the Gynecologic Cancer InterGroup. J Clin Oncol 2009;27:1419\u20131425. 212. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950\u20131955. 213."
        },
        {
            "id": "Pharmacology_Katzung_5906",
            "title": "Pharmacology_Katzung",
            "content": "Cisplatin has major antitumor activity in a broad range of solid tumors, including non-small cell and small cell lung cancer, esophageal and gastric cancer, cholangiocarcinoma, head and neck cancer, and genitourinary cancers, particularly testicular, ovarian, and bladder cancer. When used in combination regimens, cisplatin-based therapy has led to the cure of nonseminomatous testicular cancer. Cisplatin and the other platinum analogs are cleared by the kidneys and excreted in the urine. As a result, dose modification is required in patients with renal dysfunction."
        },
        {
            "id": "Gynecology_Novak_7491",
            "title": "Gynecology_Novak",
            "content": "201. Ozols RF, Bundy BN, Greer B, et al. Phase III trial of carboplatin and paclitaxel versus cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194\u20133200. 202. Du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:1320\u20131330. 203. Polverino G, Parazzini F, Stellato G, et al. Survival and prognostic factors of women with advanced ovarian cancer and complete response after a carboplatin-paclitaxel chemotherapy. Gynecol Oncol 2005;99:343\u2013347. 204. Alberts DS, Green S, Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III (suboptimal) and IV ovarian cancer. J Clin Oncol 1992;10:706\u2013717. 205."
        },
        {
            "id": "Gynecology_Novak_7303",
            "title": "Gynecology_Novak",
            "content": "six cycles, as tolerated. (Many centers modified the dose of cisplatin to 75 mg/m2 rather than 100 mg/m2 to reduce toxicity. Others substitute carboplatin (AUC 6) for cisplatin in the regimen.) The impact on outcome of these pragmatic modifications is unknown. Bevacizumab 7.5\u201315 mg/kg can be added to any of these intravenous or intraperitoneal chemotherapy regimens. In patients who cannot tolerate combination chemotherapy, single-agent, intravenously administered carboplatin (AUC 5\u20136) can be given. In patients who have a hypersensitivity to paclitaxel or carboplatin, an alternative active drug can be substituted (e.g., docetaxel, nanoparticle paclitaxel, cisplatin). In the case of carboplatin hypersensitivity, desensitization could be attempted."
        },
        {
            "id": "Gynecology_Novak_7490",
            "title": "Gynecology_Novak",
            "content": "197. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. BMJ 1991;303:884\u2013891. 198. Omura G, Bundy B, Berek JS, et al. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1989;7:457\u2013465. 199. Ovarian Cancer Meta-analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol 1991;9:1668\u20131674. 200. Swenerton K, Jeffrey J, Stuart G, et al. Cisplatincyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1992;10:718\u2013726. 201."
        },
        {
            "id": "Gynecology_Novak_7272",
            "title": "Gynecology_Novak",
            "content": "Carboplatin is widely used instead of cisplatin, as it is equivalent in efficacy and much better tolerated with significantly fewer side effects (191). A randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in 457 patients with early stage epithelial ovarian carcinoma was conducted by the GOG (192). An unexpectedly large number of patients (126 patients, 29%) had incomplete or inadequately documented surgical staging in this study. The recurrence rate for six cycles was 24% lower (HR = 0.76; confidence interval [CI], 0.5\u2013 1.13; p = 0.18) versus three cycles, but this was not statistically significant. The estimates of probability of recurrence at 5 years were 20.1% for six cycles and 25.4% for three cycles. The authors concluded that three cycles of adjuvant carboplatin and paclitaxel was a reasonable option for women with high-risk early stage ovarian cancer. The current GOG trial includes patients with high-risk stage I and stage II disease,"
        },
        {
            "id": "Gynecology_Novak_7492",
            "title": "Gynecology_Novak",
            "content": "205. McGuire WP, Hoskins WJ, Brady MS, et al. An assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 1995;13:1589\u2013 1599. 206. Ozols RF, Ostchega Y, Curt G, et al. High-dose carboplatin in refractory ovarian cancer patients. J Clin Oncol 1987;5:197\u2013201. 207. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748\u20131756. 208. The International Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002;360:505\u2013515. 209."
        },
        {
            "id": "Gynecology_Novak_7489",
            "title": "Gynecology_Novak",
            "content": "194. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1\u20136. 195. Piccart MJ, Bertelsen K, Stuart G, et al. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer 2003;13:144\u2013148. 196. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2000;18:106\u2013115. 197. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. BMJ 1991;303:884\u2013891. 198."
        },
        {
            "id": "Gynecology_Novak_7274",
            "title": "Gynecology_Novak",
            "content": "The recommendations for therapy follow: Patients with high-grade, high-risk stage I epithelial ovarian cancer should be given adjuvant chemotherapy. The type depends on the patient\u2019s overall health and medical comorbidities Treatment with carboplatin and paclitaxel chemotherapy for three to six cycles is used in these patients, whereas single agent carboplatin may be preferable for older women and patients with other medical comorbidities. Systemic multiagent chemotherapy is the standard treatment for metastatic epithelial ovarian cancer (193\u2013217). After the introduction of cisplatin in the latter half of the 1970s, platinum-based combination chemotherapy became the most frequently used treatment regimen in the United States. Paclitaxel became available in the 1980s, and this drug was incorporated into the combination chemotherapy in the 1990s (192\u2013196). Comparative trials of paclitaxel, cisplatin, and carboplatin are summarized below."
        },
        {
            "id": "Gynecology_Novak_7308",
            "title": "Gynecology_Novak",
            "content": "Cisplatin In a randomized clinical trial of intraperitoneal cisplatin for consolidation versus observation, there was no difference in survival between the treatment arms (231). Biologic Therapies As noted above, the use of the monoclonal antibody (MonAb) bevacizumab with first-line carboplatin and paclitaxel chemotherapy followed by maintenance bevacizumab for a year was associated with a modest improvement in progression-free survival, (225,226). Patients and their physicians may consider maintenance therapy with bevacizumab as delivered in GOG 218 and ICON7. There are a number of ongoing trials addressing the role of oral angiogenesis inhibitors as maintenance therapy after completion of first-line therapy in women with advanced ovarian cancer."
        },
        {
            "id": "Pharmacology_Katzung_6041",
            "title": "Pharmacology_Katzung",
            "content": "In the majority of patients, ovarian cancer remains occult and becomes symptomatic only after it has already metastasized to the peritoneal cavity. At this stage, it usually presents with malignant ascites. It is important to accurately stage this cancer with laparoscopy, ultrasound, and CT scanning. Patients with stage I disease appear to benefit from whole-abdomen radiotherapy and may receive additional benefit from combination chemotherapy with cisplatin and cyclophosphamide. Combination chemotherapy is the standard approach to stage III and stage IV disease. Randomized clinical studies have shown that the combination of paclitaxel and cisplatin provides survival benefit compared with the previous standard combination of cisplatin plus cyclophosphamide. More recently, carboplatin plus paclitaxel has become the treatment of choice. In patients who present with recurrent disease, topotecan, altretamine, or liposomal doxorubicin are used as single-agent monotherapy."
        },
        {
            "id": "Gynecology_Novak_7516",
            "title": "Gynecology_Novak",
            "content": "Rose PG, Blessing JA, Ball HG, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003;88:130\u2013135. 302. Shapiro JD, Millward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996;63:89\u201393. 303. Papadimitriou CA, Fountzilas G, Aravantinos G, et al. Second-line chemotherapy with gemcitabine and carboplatin in paclitaxelpretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study. Gynecol Oncol 2004;92:152\u2013 159. 304. Look KY, Bookman MA, Schol J, et al. Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:93\u2013100. 305."
        },
        {
            "id": "Gynecology_Novak_7512",
            "title": "Gynecology_Novak",
            "content": "286. Clarke-Pearson DL, Van Le L, Iveson T, et al. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J Clin Oncol 2001;19:3967\u20133975. 287. McGuire WP, Blessing JA, Bookman MA, et al. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2000;18:1062\u20131067. 288. Gronlund B, Hansen HH, Hogdall C, et al. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma. Cancer 2002;95:1656\u20131662. 289. Brown JV III, Peters WA III, Rettenmaier MA, et al. Threeconsecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer. Gynecol Oncol 2003;88:136\u2013140. 290. Gore M, Oza A, Rustin G, et al. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer 2002;38:57\u201363. 291."
        },
        {
            "id": "Gynecology_Novak_7517",
            "title": "Gynecology_Novak",
            "content": "305. Belpomme D, Krakowski I, Beauduin M, et al. Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study. Gynecol Oncol 2003;91:32\u201338. 306. Markman M, Webster K, Zanotti K, et al. Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol 2003;90:593\u2013596. 307. Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 1994; 12:60\u201363. 308. Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998;16:405\u2013410. 309. Perez-Gracia JL, Carrasco EM. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecol Oncol 2002;84:201\u2013209. 310."
        },
        {
            "id": "Gynecology_Novak_7290",
            "title": "Gynecology_Novak",
            "content": "A third randomized prospective GOG study (Protocol 172) compared intraperitoneal cisplatin and paclitaxel versus intravenous cisplatin and paclitaxel (214). The combination of cisplatin 75 mg/m2 and paclitaxel 135 mg/m2 given intravenously every 3 weeks was compared with paclitaxel 135 mg/m2 intravenous day 1, followed by cisplatin 100 mg/m2 intraperitoneal day 2, and paclitaxel 60 mg/m2 intraperitoneal day 8 every 3 weeks, each given for six cycles."
        },
        {
            "id": "Gynecology_Novak_7302",
            "title": "Gynecology_Novak",
            "content": "The recommended doses and schedule for intraperitoneal chemotherapy are paclitaxel 135 mg/m2 intravenous on day 1, followed by cisplatin 75 to 100 mg/m2 intraperitoneal on day 2, followed by paclitaxel 60 mg/m2 intraperitoneal on day 8, every 3 weeks for Table 37.4 Combination Chemotherapy for Advanced Epithelial Ovarian Cancer: Recommended Regimens Doxorubicin, liposomal 35\u201350 IV 3\u20134 Topotecan 1.0\u20131.25 IV 1 4.0 IV 3 (daily \u00d7 3\u20135 days) Etoposide 50 PO 3, days 14\u201321 \u2217Bevacizumab 7.5\u201315 mg/kg can be added to any of these regimens. aExcept for carboplatin dosing, where AUC\u2014area under the curve\u2014dose calculated by using Calvert formula (Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748\u20131756).bDrugs that can be substituted for paclitaxel if hypersensitivity to that drug occurs; the number of treatments administered as tolerated."
        },
        {
            "id": "Gynecology_Novak_7506",
            "title": "Gynecology_Novak",
            "content": "263. Cannistra SA. Is there a \u201cbest\u201d choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? J Clin Oncol 2002;20:1158\u20131160. 264. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 1997;8:963\u2013968. 265. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312\u2013 3322. 266. Gordon AN, Tonda M, Sun S, et al. Doxil Study 30\u201349 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004;95:1\u20138. 267."
        },
        {
            "id": "Gynecology_Novak_7509",
            "title": "Gynecology_Novak",
            "content": "274. Ghamande S, Lele S, Marchetti D, et al. Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer. Int J Gynecol Cancer 2003;13:142\u2013147. 275. Thigpen JT, Blessing JA, Ball H, et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994;12:1748\u20131753. 276. Trimble EL, Adams JD, Vena D, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993;11:2405\u20132410. 277. Bookman MA, Malstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998;16:3345\u2013 3352. 278."
        },
        {
            "id": "Gynecology_Novak_7510",
            "title": "Gynecology_Novak",
            "content": "278. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183\u20132193. 279. ten Bokkel Huinink W, Lane SR, Ross GA; International Topotecan Study Group. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 2004;15:100\u2013103. 280. Hoskins P, Eisenhauer E, Beare S, et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1998;16:2233\u20132237. 281. Markman M, Blessing JA, Alvarez RD, et al. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2000;77:112\u2013115. 282."
        },
        {
            "id": "Gynecology_Novak_7484",
            "title": "Gynecology_Novak",
            "content": "173. Berek JS. Adjuvant therapy for early-stage ovarian cancer. N Engl J Med 1990;322:1076\u20131078. 174. Ahmed FY, Wiltshaw E, Hern RP, et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 1996;14:2968\u20132975. 175. Finn CB, Luesley DM, Buxton EJ, et al. Is stage I epithelial ovarian cancer overtreated both surgically and systemically? Results of a five-year cancer registry review. Br J Obstet Gyn 1992;99:54\u201358. 176. Vergote I, Vergote S, De Vos LN, et al. Randomized trial comparing cisplatin with radioactive phosphorus or whole abdominal irradiation as adjuvant treatment of ovarian cancer. Cancer 1992;69:741\u2013 749. 177. Rubin SC, Wong GY, Curtin JP, et al. Platinum based chemotherapy of high risk stage I epithelial ovarian cancer following comprehensive surgical staging. Obstet Gynecol 1993;82:143\u2013147. 178."
        },
        {
            "id": "Gynecology_Novak_7268",
            "title": "Gynecology_Novak",
            "content": "Because cisplatin, carboplatin, cyclophosphamide, and paclitaxel (Taxol) are active single agents against epithelial ovarian cancer, these drugs are administered in various combinations. There are some series in which cisplatin or cyclophosphamide (PC) or both have been used to treat patients with stage I disease (176\u2013181). In a GOG trial of three cycles of cisplatin and cyclophosphamide versus intraperitoneal chromic phosphate (32P) in patients with stage IB and IC disease, the progression-free survival of women receiving the platinum-based chemotherapy was 31% higher than those receiving the radiocolloid (178). Similar results were reported by a multicenter trial performed in Italy by the Gruppo Italiano Collaborativo Oncologica Ginecologica (GICOG) for progression-free survival, although there was no overall survival advantage (179)."
        },
        {
            "id": "Gynecology_Novak_7375",
            "title": "Gynecology_Novak",
            "content": "Table 37.6 Combination Chemotherapy for Germ Cell Tumors of the Ovary Bleomycin 15 units/m2/week \u00d7 5; then on day 1 of course 4 Etoposide 100 mg/m2/day \u00d7 5 days every 3 weeks Cisplatin 20 mg/m2/day \u00d7 5 days, or 100 mg/m2/day \u00d7 1 day Vinblastine 0.15 mg/kg days 1 and 2 every 3 weeks Bleomycin 15 units/m2/week \u00d7 5; then on day 1 of course 4 Cisplatin 100 mg/m2 on day 1 every 3 weeks Vincristine 1\u20131.5 mg/m2 on day 1 every 4 weeks Actinomycin D 0.5 mg/day \u00d7 5 days every 4 weeks Cyclophosphamide 150 mg/m2/day \u00d7 5 days every 4 weeks a All doses given intravenously."
        },
        {
            "id": "Gynecology_Novak_7076",
            "title": "Gynecology_Novak",
            "content": "(200,201). Doublet therapy with cisplatin and paclitaxel is considered standard therapy based on GOG 204, which analyzed four cisplatin-containing doublets for the best efficacy; although no major differences existed in overall survival for the four doublets, the cisplatin and paclitaxel doublet trended toward the best results (153). Other studies showed comparable survival and less toxicity with carboplatin and paclitaxel (154)."
        },
        {
            "id": "Gynecology_Novak_7499",
            "title": "Gynecology_Novak",
            "content": "231. Piccart MJ, Floquet A, Scarfone G, et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer 2003;13(Suppl 2):196\u2013203. 232. Berek JS, Taylor PT, Gordon A, et al. Randomized placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 2004;22:3507\u20133516. 233. Berek H, Taylor P, McGuire W, et al. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 2009;27:418\u2013425. 234. Verheijen RH, Massuger LF, Benigno BB, et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol 2004;22:2635\u2013 2642. 235."
        },
        {
            "id": "Gynecology_Novak_7025",
            "title": "Gynecology_Novak",
            "content": "MVAC was compared to cisplatin alone, and cisplatin combined with topotecan. The MVAC arm was prematurely closed because of excessive toxicity, and the remaining cisplatin arms were compared. Although the combination of cisplatin and topotecan was superior to cisplatin alone, the improvement in overall survival was only 3 months. The combination arm had a higher complete response rate, overall response rate, progression-free survival, and overall survival (152). Doublet therapy with cisplatin and paclitaxel is considered standard therapy based on GOG 204, which analyzed four cisplatin-containing doublets (topotecan, paclitaxel, vinorelbine, and gemcitabine) for the best efficacy; although no major differences existed in overall survival for the four doublets, the cisplatin and paclitaxel doublet trended toward the best results (153). Overall, it appears that multiagent regimens offer an improved response rate and slightly higher overall survival but with increased toxicity. Other"
        },
        {
            "id": "Gynecology_Novak_7513",
            "title": "Gynecology_Novak",
            "content": "290. Gore M, Oza A, Rustin G, et al. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer 2002;38:57\u201363. 291. Homesley HD, Hall DJ, Martin DA, et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol 2001;83:394\u2013399. 292. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099\u2013 2106. 293. Gonzalez-Martin AA, Calvo E, Bover I, et al. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann Oncol 2005;16:749\u2013755. 294."
        },
        {
            "id": "Gynecology_Novak_7286",
            "title": "Gynecology_Novak",
            "content": "Figure 37.15 Survival of patients with stage III epithelial ovarian cancer treated with carboplatin and paclitaxel versus cisplatin and paclitaxel: a Gynecologic Oncology Group study. 0.2 0.1 A: Survival by treatment. B: Survival by treatment group (micro vs. macro). (From Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2003;21:3194\u20133200, with permission; Berek JS, Hacker NF. Berek & Hacker\u2019s Gynecologic Oncology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2010:475, with permission.)"
        },
        {
            "id": "Gynecology_Novak_7494",
            "title": "Gynecology_Novak",
            "content": "213. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose intravenous carboplatin followed by intraperitoneal paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian cancer: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and the Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001\u20131007. 214. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Medl 2006;354:34\u201343. 215. Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2006;100:27\u201332. 216."
        },
        {
            "id": "Gynecology_Novak_7276",
            "title": "Gynecology_Novak",
            "content": "Reporting the GOG data (Protocol 111), McGuire et al. showed that the combination of cisplatin (75 mg/m2) and paclitaxel (135 mg/m2) was superior to cisplatin (75 mg/m2) and cyclophosphamide (600 mg/m2), each given for six cycles (194). In suboptimally resected patients, the paclitaxel-containing arm produced a 36% reduction in mortality. These data were verified in a trial conducted jointly by the EORTC, the Nordic Ovarian Cancer Study Group (NOCOVA), and the National Cancer Institute of Canada (NCIC), in which patients with both optimal and suboptimal disease were treated (195). In this study, the paclitaxel-containing arm produced a significant improvement in both progression-free interval and overall survival in both optimal and suboptimal groups. Based on these two studies, paclitaxel is included in the primary treatment of all women with advanced-stage epithelial ovarian cancer, unless there are contraindications to paclitaxel, such as preexisting peripheral neuropathy."
        }
    ],
    "scores": [
        0.035495209206028215,
        0.03381126682458325,
        0.03326058135994191,
        0.03278558320323201,
        0.031293466509878395,
        0.030090547732560022,
        0.029810578577619474,
        0.029614192353135498,
        0.029291678912695927,
        0.029176764123549113,
        0.027607543625440715,
        0.02677750717946143,
        0.0264558518713143,
        0.026394217995510103,
        0.026355514232431883,
        0.02598375613642789,
        0.025829562594268475,
        0.02575142272031819,
        0.02546731353934909,
        0.02456997592710606,
        0.024246614485003724,
        0.02415747690977049,
        0.024065542951978575,
        0.023997741389045736,
        0.023988092235178803,
        0.023785983379610718,
        0.02318571057508064,
        0.022957479125939134,
        0.022854974247763622,
        0.022288630332720966,
        0.021347986706218416,
        0.02097814035886058
    ]
}